• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Nivalis Therapeutics restructures

Nivalis Therapeutics restructures

January 16, 2017
CenterWatch Staff

Nivalis Therapeutics, a clinical stage pharmaceutical company focused on developing innovative solutions for people with cystic fibrosis (CF), has announced that its board of directors has approved a restructuring plan as part of the company’s initiative to explore strategic alternatives focused on maximizing stockholder value from its clinical assets and cash resources.

The company intends to complete a reduction in force affecting 25 employees, including Jon Congleton, president and chief executive officer, and David Rodman, M.D., chief medical officer and executive vice president of Discovery. The reductions are expected to occur between January 15, 2017 and March 31, 2017, after which, the company will have approximately five remaining employees. As a result of the restructuring plan, the company estimates that it will incur cash severance costs of approximately $3 million, which are expected to be paid during the first half of 2017.

The reduction in force is intended to preserve the company’s cash while it assesses various strategic alternatives, as announced earlier this month. The company currently projects that it will have approximately $45-$47 million of net cash available for the potential strategic transaction. This projection is based on the company’s current expectations and assumptions, including the consummation of a transaction during the third quarter of 2017, and the actual amount of net cash available could differ materially from the company’s current estimate.

“We are extremely grateful for the outstanding leadership of Congleton and the many contributions of Dr. Rodman, as well as our other impacted employees, who have dedicated themselves to Nivalis’ efforts in cystic fibrosis,” said Howard Furst, M.D., chairman of the board of directors. “Nivalis is committed to maximizing shareholder value by preserving the Company’s cash, and unfortunately this necessitates the announced restructuring.”

Congleton will be stepping down from his role as president and chief executive officer effective January 15, 2017, at which time he will also resign from the board of directors.

The board of directors has appointed Michael Carruthers, the company’s chief financial officer, as interim president, effective January 15, 2017.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing